Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China | |
Zhang, Qingyuan; Shao, Zhimin; Shen, Kunwei; Li, Li; Feng, Jifeng; Tong, Zhongsheng; Gu, Kangsheng; Wang, Xiaojia; Xu, Binghe; Sun, Guofang | |
刊名 | ONCOTARGET
![]() |
2016 | |
卷号 | 7期号:35 |
关键词 | advanced breast cancer fulvestrant endocrine therapy hormone receptor-positive breast cancer |
ISSN号 | 1949-2553 |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3627804 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Zhang, Qingyuan,Shao, Zhimin,Shen, Kunwei,et al. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China[J]. ONCOTARGET,2016,7(35). |
APA | Zhang, Qingyuan.,Shao, Zhimin.,Shen, Kunwei.,Li, Li.,Feng, Jifeng.,...&Jiang, Zefei.(2016).Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.ONCOTARGET,7(35). |
MLA | Zhang, Qingyuan,et al."Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China".ONCOTARGET 7.35(2016). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论